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Abstract 
After decades in PtdIns(3,4,5)P3’s shadow, PtdIns(3,4)P2 has now emerged as a bona fide regulator of 
important cellular events, including endocytosis and cell migration.  New understanding of 
PtdIns(3,4)P2’s cellular roles has been possible via novel approaches to observe and quantify cellular 
PtdIns(3,4)P2 dynamics, alongside methods to target the kinases and phosphatases governing 
phosphoinositide turnover.  Despite this, the mechanisms by which PtdIns(3,4)P2 orchestrates its 
cellular roles remain more poorly understood, most notably because, to date, few PtdIns(3,4)P2 
effectors have been identified.  Here, we develop and apply an affinity-proteomics strategy to conduct 
a global screen for PtdIns(3,4)P2 interactors in human platelets; a primary cell type with striking 
PtdIns(3,4)P2 accumulation.  Through an integrated approach, coupling affinity capture of 
PtdIns(3,4)P2-binding proteins to both label-free and isobaric tag-based quantitative proteomics, we 
identify a diverse PtdIns(3,4)P2 interactome.  Included are long-established PtdIns(3,4)P2-binding 
proteins such as PLEKHA1, PLEKHA2, AKT and DAPP1, and a host of potentially novel effectors, 
including MTMR5, PNKD, RASA3 and GAB3.  The PtdIns(3,4)P2 interactome shows an enrichment 
of pleckstrin homology (PH) domain-containing proteins, and through bioinformatics and array 
analyses we characterise the PH domain of MTMR5 and define its phosphoinositide selectivity.  The 
interactome is also diverse in function, including several proteins known to support protein trafficking 
and cytoskeletal mobilisation.  Such proteins have the ability to drive key platelet events, and to fulfil 
recently-defined roles for PtdIns(3,4)P2 in a wider range of cell types.  Moreover, this study will serve 
as a valuable resource for the future characterisation of effector-driven PtdIns(3,4)P2 function. 
 
1. Introduction 
Phosphoinositides regulate diverse and essential cellular processes, most commonly via interactions 
with versatile sets of effector proteins.  The best-characterised example is the Class I phosphoinositide 
3-kinase (PI3K) product, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), which coordinates 
the plasma membrane recruitment and/or activity of effectors such as AKT, BTK and ARAP1 to 
control cellular processes including metabolism, growth and migration.  In contrast to the extensive 
functional characterisation of PtdIns(3,4,5)P3 over the past three decades, phosphatidylinositol 3,4-
bisphosphate (PtdIns(3,4)P2) has been described as a “neglected phosphoinositide” [1] and has been 
relatively overlooked, largely because it was long considered to be little more than a by-product of 
PtdIns(3,4,5)P3 signal termination by 5-phosphatases [1, 2].  However, work in recent years has shed 
new light on the importance of PtdIns(3,4)P2 as a signalling phospholipid in its own right.  Indeed, a 
number of studies have revealed roles for PtdIns(3,4)P2 in the regulation of endocytosis [3, 4], 
membrane morphology [5, 6], cell polarization [7] and migration [8], while also suggesting 
significance in cancer [9-12].   
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Despite this new functional appreciation, PtdIns(3,4)P2 remains enigmatic in many regards.  While a 
number of phosphoinositide kinases and phosphatases have been proposed to contribute to the 
synthesis (e.g. PI3KC2α/β/γ, SHIP1/2, INPP5B/E/J, SYNJ2) and degradation (e.g. INPP4A/B, PTEN) 
of PtdIns(3,4)P2, the complete set and balance of enzymes regulating the turnover of this 
phosphoinositide in vivo, and the details of their dynamic regulation, remain unclear and appear to be 
highly context dependent [2-4, 11, 13].  Moreover, although generally considered to act via the 
membrane recruitment of effector proteins in a manner analogous to PtdIns(3,4,5)P3, mechanistic 
understanding of how PtdIns(3,4)P2 regulates cell function following synthesis remains limited, 
because only a modest number of effectors have been identified [14].    
Of the known PtdIns(3,4)P2 effectors, among the best-characterised are those also regulated by 
PtdIns(3,4,5)P3; most notably AKT and PDK1.  The functional significance of this dual affinity and 
the relative contribution of the two lipids to protein regulation in specific signalling contexts is 
challenging to dissect.   Indeed it has been proposed that PtdIns(3,4)P2 can both support and inhibit 
Class I PI3K/PtdIns(3,4,5)P3 signalling via both distinct and overlapping effectors [1, 2, 11, 15-18].  
A small number of proteins have been reported to show clear selectivity for PtdIns(3,4)P2 over other 
phosphoinositides - most notably PLEHKA1 and 2 (commonly known as TAPP1 and 2) [19-21], but 
also Lamellipodin [22] - and the characterisation of such effectors has helped uncover functional roles 
for PtdIns(3,4)P2 in different cell types [16, 17, 23].  Despite this progress, the network of known 
PtdIns(3,4)P2 effectors remains limited [14], and it is unclear whether PtdIns(3,4)P2 is able to regulate 
a wider family of proteins comparable to that of PtdIns(3,4,5)P3.   
Global cellular PtdIns(3,4)P2 accumulation in response to cell surface receptor activation is commonly 
slower and more sustained than that of PtdIns(3,4,5)P3, although distinct phosphoinositide pools may 
display unique kinetics [2, 13, 24, 25].  Stimulated platelets generate a striking quantity of 
PtdIns(3,4)P2 relative to many cell types [2, 11, 26-30] and, as their function is critically dependent on 
PI3K signalling [14], they represent an excellent primary cell model for the characterisation of 3-
phosphoinositide biology.  Furthermore, the use of platelets has previously supported advances in the 
understanding of PtdIns(3,4)P2 behaviour and function [11, 26-28, 31], and thus these cells would 
serve as an excellent vehicle for the identification of PtdIns(3,4)P2 effectors.  While the precise 
functional role of PtdIns(3,4)P2 remains unclear, its production in platelets is strongly dependent on 
αIIbβ3 integrin engagement, and has been proposed to support platelet aggregation and cytoskeletal 
arrangements required for thrombus formation [14, 26, 27, 29].  Its accumulation correlates with a 
decline of the initial rapid PtdIns(3,4,5)P3 generation following cell surface receptor activation, and 
accordingly has been shown to be heavily dependent on the PtdIns(3,4,5)P3 5-phosphatase, SHIP1 
[32]. Platelets lacking SHIP1 show striking defects in platelet signalling and thrombus formation, 
potentially due to observed changes in the PtdIns(3,4,5)P3/ PtdIns(3,4)P2 balance [32, 33].  Here, we 
couple affinity capture of PtdIns(3,4)P2-binding proteins from human platelet lysates, to label-free and 
isobaric tag-based quantitative mass spectrometry, in order to define a global cellular PtdIns(3,4)P2 
interactome.  We present this dataset to support new understanding of PtdIns(3,4)P2’s role in platelets, 
but also as a general resource to facilitate improved understanding of PtdIns(3,4)P2 effectors and their 
role in the regulation of important aspects of cell function.      
 
2. Materials and methods 
2.1 Materials 
Antibodies against RASA3 (sc-166442 and sc-34468), PLEKHA1 (sc-50468), ADAP1 (sc-47836) 
and GAPDH (sc-25778) were from Santa Cruz Biotechnology (Insight Scientific, Middlesex, UK).  
The antibody against PHLDB1 (HPA038448) was from Sigma Aldrich (Poole, UK).  The antibody 
against DAPP1 (AF7024) was from R&D Systems (Abingdon, UK). The antibody against GST 
(2622) and DyLight 680/800 secondary antibodies were from Cell Signaling Technologies (New 
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England Biolabs, Hitchin, UK).  Anti-rabbit HRP-coupled secondary antibody was from Jackson 
ImmunoResearch (Stratech Scientific Ltd, Ely, UK).  Immobilon FL polyvinylidene difluoride 
(PVDF) was from Merck Millipore (Dorset, UK).  Odyssey blocking buffer (TBS) was from LI-COR 
Biosciences (Cambridge, UK).  Blank control beads, PtdIns(3,4)P2 beads (P-B034A), free 
PtdIns(3,4)P2 (P-3408) and PIP Arrays (P-6100) were from Echelon Biosciences, distributed via 
Tebu-Bio (Peterborough, UK). cOmplete mini protease inhibitor tablets were from Roche Life 
Sciences (Welwyn Garden City, UK). Tandem Mass Tag reagents and NuPAGE sample buffer were 
from Thermo Fisher Scientific (Loughborough, UK). Leukocyte removal filters were from Pall 
(Portsmouth, UK).  All other reagents were from Sigma Aldrich (Poole, UK) unless otherwise stated 
in the relevant methods subsection.  
2.2 Human platelet preparation 
Venous blood, drawn into a syringe containing 4% trisodium citrate (9:1, volume-to-volume), was 
obtained from healthy, medication-free, human volunteers.  The study was conducted with the 
approval of the local research ethics committee at the University of Bristol, and volunteers gave full 
informed consent in accordance with the Declaration of Helsinki. Platelets were isolated as previously 
described [34], utilising a protocol developed to minimize plasma, erythrocyte, and leukocyte protein 
contamination. The platelet suspension was allowed to rest for 30 minutes at 30°C before use.  
2.3 Affinity capture of platelet PtdIns(3,4)P2-binding proteins  
Purified platelets were centrifuged (520g, 10 minutes, room temperature), and the pellet was lysed in 
ice-cold lysis buffer (20 mM HEPES [pH 7.4], 120 mM NaCl, 0.5% NP40, 5 mM EGTA, 5 mM 
EDTA, 5 mM β-glycerophosphate, 10 mM sodium fluoride, 1 mM sodium orthovanadate, cOmplete 
mini protease inhibitor tablet). Phosphatase inhibitors were included to preserve the identity of 
PtdIns(3,4)P2 on the beads [31, 35].  Lysates were freeze-thawed, vortexed, and centrifuged (12000g, 
10 minutes, 4°C) to provide final clarified samples.  A total of 8x10
8
 platelets were used per sample 
for proteomics experiments. Blank control beads or PtdIns(3,4)P2-coupled beads were prewashed 3x 
with ice-cold lysis buffer by low speed centrifugation, before affinity capture was performed by 
incubating platelet lysate with the control or PtdIns(3,4)P2-coupled beads for 90 minutes at 4°C under 
gentle rotation. For competition control samples, lysates were preincubated with 40 µM free 
PtdIns(3,4)P2 for 30 minutes prior to PtdIns(3,4)P2 bead incubation.  Following the incubation, beads 
were washed 3x with either ice-cold lysis buffer, or ice-cold 20 mM HEPES [pH 7.4], 120 mM NaCl, 
0.5% NP40 (for TMT samples), by low speed centrifugation.  Proteins were either eluted from the 
beads by heating to 95
o
C in NuPAGE LDS sample buffer (plus 50 mM dithiothreitol) for 10 minutes 
(immunoblotting or label-free LC-MS/MS analysis), or trypsin-digested directly on the beads (TMT 
analysis), as discussed in the relevant Supplementary Methods sections.   
2.4 Platelet PtdIns(3,4)P2 interactome analysis by mass spectrometry  
A brief description is given here, with full details in Supplementary Methods. For label-free 
experiments, pull down eluates (3 per donor, 3 independent donors) in sample buffer were run into an 
SDS-PAGE gel and each gel lane (eluate) cut into 5 slices. Each slice was subjected to in-gel trypsin 
digestion using a DigestPro automated digestion unit (Intavis Ltd, Koln, Germany). The resulting 
peptides were fractionated using an Ultimate 3000 nanoHPLC system in line with an Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific, Loughborough, UK).  For TMT experiments, 
on-bead trypsin digestion was carried out for each pull down sample (3 per donor, 2 independent 
donors), peptides were labelled with Tandem Mass Tag (TMT) sixplex reagents according to the 
manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, UK), and the labelled samples 
were pooled.  The pooled sample was evaporated to dryness, resuspended in formic acid and then 
desalted using a SepPak cartridge according to the manufacturer’s instructions (Waters, Elstree, UK).  
Eluate from the SepPak cartridge was again evaporated to dryness and resuspended prior to 
fractionation by high pH reversed-phase chromatography using an Ultimate 3000 liquid 
chromatography system (Thermo Fisher Scientific, Loughborough, UK).  High pH RP fractions were 
further fractionated using an Ultimate 3000 nano-LC system in line with an Orbitrap Fusion Tribrid 
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mass spectrometer (Thermo Fisher Scientific, Loughborough, UK).  Full details of data analysis are 
given in Supplementary Methods.   
2.5 Bioinformatics 
Protein domain enrichment analysis was conducted using the InterPro output from DAVID [36, 37] 
version 6.8.   Interaction network analysis was conducted using STRING [38] version 11, searching 
for experimentally-determined and databased-curated interactions, with a confidence score of 0.9.  PH 
domain sequence alignment was carried out using Clustal Omega 1.2.4 [39].  The MTMR5 PH 
domain structure was rendered in PyMOL 2.1.1 using conformer 1 of PDB entry 1V5U, with the 
relevant amino acid side chains highlighted, as discussed in the text.   
2.6 Immunoblotting 
Pull down eluates and input samples were resolved by electrophoresis and transferred onto Immobilon 
FL PVDF membrane following standard procedures [40]. For some experiments, membranes were cut 
into sections to allow multiple proteins to be probed separately with different primary antibodies. 
Proteins were visualized by near-infrared detection using a LI-COR® Odyssey imaging system and 
DyLight 680/800 secondary antibodies. LI-COR® Image Studio was used to prepare figures. 
2.7 MTMR5 PH domain expression 
DNA sequence corresponding to residues 1752-1868 of human MTMR5 was optimised for E. Coli 
expression and cloned into the BamHI-EcoRI sites of pGEX-4-T1 (Genscript, New Jersey, USA).  
Protein was expressed in BL21 cells, purified from lysates using glutathione sepharose and eluted 
with 15mM reduced L-glutathione, as previously described [41]. 
2.8 MTMR5 phosphoinositide arrays 
PIP array membranes were incubated in blocking buffer (3% fatty acid-free BSA in 20mM Tris, 
150mM NaCl, 0.1% Tween (TBS-T)) for 1 hour at room temperature.  Purified GST-MTMR5 PH 
domain was diluted in blocking buffer to a final concentration of 0.5µg/ml and incubated with the 
membrane for 1 hour at room temperature, before washing four times in TBS-T for 10 minutes per 
wash.  The membrane was then incubated with anti-GST primary antibody at a dilution of 1:1000 in 
blocking buffer for 1 hour at room temperature, before a further four washes, and incubation with an 
HRP-conjugated anti-rabbit secondary antibody at a dilution of 1:10000 in blocking buffer for 1 hour 
at room temperature.  After a final four washes of the membrane, the interaction between the MTMR5 
PH domain and phosphoinositides was detected by enhanced chemiluminescence.   
 
3. Results 
We have previously utilised affinity proteomics to define the PtdIns(3,4,5)P3 interactome of human 
platelets, allowing the identification and subsequent functional characterisation of Class I PI3K 
effectors regulating important platelet signalling events [34, 41].  We therefore set out to apply a 
similar approach to identify PtdIns(3,4)P2 effectors, with the aim of providing a valuable data 
resource to advance understanding of this more poorly-characterised phosphoinositide.  Affinity 
proteomics experiments were conducted using human platelet lysates as outlined in Figure 1.  As 
platelet proteomics can be confounded by contamination of samples with proteins derived from blood 
plasma, or from co-purified leukocytes and erythrocytes, we utilised an optimised human platelet 
purification protocol [34] to obtain platelet fractions, and used freshly-isolated platelets to avoid 
proteome degradation.  Furthermore, because affinity proteomics is inevitably prone to the capture of 
non-specific proteins, in addition to the use of PtdIns(3,4)P2-coupled beads, we incorporated 
independent control samples utilising blank bead capture, or free-PtdIns(3,4)P2 competition, to 
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confirm binding specificity.  We also utilised fractionation at the protein and peptide level to reduce 
sample complexity and to limit crowding out of lower abundance interactors.   
An initial global analysis of the label-free data across the three blood donors identified a number of 
known PtdIns(3,4)P2-binding proteins in our screen, including the archetypal PtdIns(3,4)P2 effectors, 
PLEKHA1, PLEKHA2 and DAPP1, thus validating our approach (Figure 2).  Of note, visualising this 
analysis revealed the striking number of proteins demonstrating enrichment on the PtdIns(3,4)P2 
beads when compared to blank control beads (Figure 2A), and emphasized the importance of our dual 
controlled approach, with our free-PtdIns(3,4)P2 competition experiments confirming only a 
proportion of the PtdIns(3,4)P2 bead proteome to show PtdIns(3,4)P2 specificity (Figure 2B).  This 
highlights the challenge of identifying hits when relying on a single bait capture for identifying 
phosphoinositide-binding proteins (see Figure 2C for a range of protein behaviours), as has been the 
approach in several previous published screens, and the importance of a quantitative methodology.  
With this in mind, to obtain our final comprehensive PtdIns(3,4)P2 interactome, we utilised a 
quantitative filtering approach within and across the label-free datasets of the three blood donors, 
followed by cross referencing with an independent dataset from multiplexed affinity proteomics 
experiments carried out utilising isobaric labelling of peptides with tandem mass tags (TMT).  The 
latter approach permits pooling of samples at the peptide level, minimising technical variation in the 
LC-MS runs and providing a direct, ratiometric readout.   
This integrated approach defined a diverse PtdIns(3,4)P2 interactome (Table 1 & Table S1), including 
the aforementioned classically-described PtdIns(3,4)P2-binding proteins, and additional endogenous 
platelet proteins for which PtdIns(3,4)P2 affinity has been previously proposed via other approaches, 
such as ADAP1, PHLDB1 and SWAP70 [20, 21, 42-44].  Moreover, our dataset includes a range of 
further proteins likely to represent novel PtdIns(3,4)P2-regulated proteins, including PNKD, RASA3, 
MTMR5, GAB3 and PLEKHO2.  Importantly, while proteins such as DAPP1, AKT and RASA3 have 
been previously defined as important signalling nodes in human and mouse platelets [34, 41, 45, 46], 
the function of a large proportion of the proteins identified, including the well-established 
PtdIns(3,4)P2 effectors PLEKHA1 and 2, remains unknown in this cell type, and so for many proteins 
this study is the first insight into their functional regulation.  The specificity of our approach was 
validated by the absence of proteins specific for other phosphoinositides in our dataset; most notably 
PtdIns(3,4,5)P3-specific effectors such as BTK, Tec, and DOCK-family proteins.  Such proteins are 
highly expressed in platelets, and were abundantly purified in our previous PtdIns(3,4,5)P3 
interactome screen [34].  Furthermore, the absence of the known PtdIns(3,4)P2-binding protein 
Lamellipodin [23], which is highly expressed in lymphocytes, but not in platelets [47], supports the 
purity of our platelet preparation.   
We confirmed a subset of hits from our proteomics screen by immunoblotting (Figure 3), which gave 
further insights into the relative affinity of the proteins for PtdIns(3,4)P2 under our experimental 
conditions. To our knowledge, this included the first evidence of the affinity of some of these full 
length, endogenous proteins for PtdIns(3,4)P2 including, of note, RASA3, a protein critical for 
integrin signalling and platelet function [41, 48].  The DAPP1 PH domain has been reported to have 
high affinity for PtdIns(3,4)P2 and, in agreement with previous work [34, 49], DAPP1 was captured 
highly efficiently on the PtdIns(3,4)P2-coupled beads.  PLEKHA1 was challenging to detect in 
platelet lysates by immunoblotting, suggesting it may be expressed at relatively low levels in this cell 
type, consistent with published expression data [47, 50].  Despite this, this protein was highly 
enriched on the PtdIns(3,4)P2 beads, supporting the high affinity of the PLEKHA1/2 proteins for this 
phospholipid and suggesting they could likely respond adequately to localised PtdIns(3,4)P2 in 
platelets.  
Our interactome contained multiple PH domain-containing proteins (Figure 4A), which ontology 
analysis confirmed to be significantly enriched in the dataset (Figure 4B) in line with the recognized 
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importance of a subset of this protein domain family in PtdIns(3,4)P2 (as well as PtdIns(3,4,5)P3) 
binding [51].  This analysis also revealed MTMR1 and FRMD4B to possess pleckstrin homology-like 
domains which, in addition to cytohesin binding, may also support the regulation of the latter by 
PtdIns(3,4,5)P3 [34].  Other protein domains associated with PtdIns(3,4,5)P3 binding, such as the 
DHR-1 domain of DOCK family proteins [34, 52], were not enriched in the interactome, further 
supporting the specificity of our approach.  Previous work has defined key residues within certain PH 
domains which are important for their interaction with PtdIns(3,4)P2 and PtdIns(3,4,5)P3 [51, 53-56].  
We performed sequence alignment analysis of the PH domains identified in our screen, which 
confirmed several, including those of GAB3, MTMR5 and PLEKHO2, to possess a pattern of 
conserved basic residues in a previously-described KXn(K/R)XR motif in the β1-β2 strand region [51, 
54, 57] (Figure 4A). Interestingly, SWAP70 and OSBL8 diverged from this motif, with the latter 
lacking it completely, despite our study being in agreement with others that the PH domains of both of 
these proteins interact directly with PtdIns(3,4)P2 [44, 58].  This can be explained by the presence of 
additional basic residues, including the RR motif in the β1-β2 loop of SWAP70 [44], and K/R 
residues in the β1-β2 and β5-β6 loops of OSBL8 [58], with PtdIns(3,4)P2 likely binding the latter via 
a non-canonical basic pocket comparable to that of ARHGAP9 [56].  Further residues within PH 
domains also contribute to PtdIns(3,4)P2- and PtdIns(3,4,5)P3-binding [51, 57], while other regions of 
the protein may be important [59], making phosphoinositide effector identification challenging from a 
purely computational approach, and supporting the continued need for experimental identification.   
Assessment of the structure of the PH domain of mouse MTMR5 confirmed a characteristic seven-
stranded β-sandwich with a C-terminal α-helix (Figure 5A).  Mapping of the highly conserved basic 
residues from our alignment of the MTMR5 PH domain onto this structure revealed their localisation 
to form a potential phosphoinositide-binding pocket comparable to that previously defined for DAPP1 
and other PtdIns(3,4)P2/PtdIns(3,4,5)P3 effectors [57, 60].   In this pocket, the basic amino acid 
sidechains can form multiple hydrogen bonds with the phosphates of the inositol headgroup [60], and 
thus these observations further support our identification of MTMR5 as a PtdIns(3,4)P2 interactor. 
Comparison of the PH domain of MTMR5 to dual PtdIns(3,4)P2/PtdIns(3,4,5)P3 effectors such as 
DAPP1 also suggested MTMR5 may have the potential to interact not only with PtdIns(3,4)P2, but 
also with PtdIns(3,4,5)P3.  To assess this, and to also determine MTMR5’s wider phosphoinositide 
selectivity, we expressed the PH domain of human MTMR5 as a GST-fusion protein (Figure 5B), and 
carried out lipid binding arrays against all phosphoinositides.  This confirmed the affinity of the 
MTMR5 PH domain for PtdIns(3,4)P2, while indeed also revealing some affinity for PtdIns(3,4,5)P3 
(Figure 5C).    
A high confidence network analysis of our dataset using STRING [38] revealed minimal known 
protein-protein interactions amongst the proteins identified (Figure 6), suggesting the majority were 
captured directly on the PtdIns(3,4)P2 beads, rather than being present as indirect components of the 
wider PtdIns(3,4)P2 signalosome.  Functional consideration of the platelet PtdIns(3,4)P2 interactome 
reveals a number of signalling ‘adaptors’ lacking conventional catalytic function (e.g. DAPP1, 
PLEKHA1, PLEKHA2, GAB3, PHLDB1), in addition to enzymes (e.g. AKT, PDK1, PFKP, AGK) 
and regulators of GTPase activity (e.g. RASA3, MTMR5, ADAP1).   The interactome also includes 
candidates associated with small molecule transport (e.g. SLC25A1, ORNT1), mitochondrial function 
(e.g. SQOR, MICU1, DECR1), and receptors (e.g. GPVI, P2RX1, F2RL3), highlighting the diversity 
of processes regulated by PtdIns(3,4)P2, and opening avenues for novel exploration with regards to 
the cellular roles of this phospholipid.   
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4. Discussion 
After years on the side-lines, a number of recent studies have shed light on the role of PtdIns(3,4)P2 as 
a bona fide regulator of important cellular processes [3-5, 7-11].  The development of new tools and 
methodologies to manipulate enzymes in the PtdIns(3,4)P2 synthetic pathway, and to observe and 
quantify PtdIns(3,4)P2 (and other phosphoinositides) in biological contexts, has permitted new 
understanding of its synthesis and degradation, distinct cellular roles, and likely significance in 
disease [11, 13, 18, 61].  Despite these recent advances, knowledge of the effectors allowing 
PtdIns(3,4)P2 to drive important cellular processes remains limited [14]. Furthermore, despite 
progress in other cell types, the mechanistic and functional action of this phospholipid in platelets 
remains poorly understood, despite observations of PtdIns(3,4)P2 accumulation in platelets occurring 
three decades ago [26-28].  Indeed, the study of PtdIns(3,4)P2 in platelets has remained largely limited 
to observations of the temporal patterns of synthesis and degradation, and potential roles in AKT 
regulation [11, 27, 29, 30, 62, 63].  PtdIns(3,4)P2 accumulation in platelets is most striking following 
integrin αIIbβ3 engagement and platelet aggregation, and has been proposed to sustain or strengthen 
platelet aggregation, potentially in part by supporting cytoskeletal changes [14, 26, 29].  This 
relatively late accumulation of PtdIns(3,4)P2 correlates with a decline in an initial, rapid 
PtdIns(3,4,5)P3 spike following platelet activation, and is heavily dependent on SHIP1 5-phosphatase 
activity [32, 64, 65].  Class II PI3Ks can also produce distinct pools of PtdIns(3,4)P2 to support events 
such as clathrin-dependent endocytosis at the plasma membrane and endosomal mTOR suppression in 
some cell types [3, 4].  However, while PI3KC2α plays an important role in platelet membrane 
structure and function, Class II PI3Ks do not appear to be clearly important for agonist-induced 
PtdIns(3,4)P2 production in platelets [66-68].  
Our proteomics screen confirmed that human platelets possess a core set of PtdIns(3,4)P2 effectors 
observed previously using in vitro approaches or other cell types, including AKT, PDK1, DAPP1 and 
PLEKHA1 and 2.  The AKT isoforms and PDK1 have important roles in platelet activation and 
thrombus formation in response to the activation of various cell surface receptors [45, 46], and we 
have previously defined a key role for DAPP1 downstream of glycoprotein VI [34].  In contrast, the 
roles of the tandem PH domain-containing adaptors PLEKHA1 and PLEKHA2 in platelets remain 
unknown.  These adaptor proteins can provide negative feedback of insulin and PI3K signalling 
pathways, and in B cells PLEKHA1/2 can regulate cellular adhesion and migration, germinal center 
responses, and metabolism [1, 16, 17, 19, 69, 70].  The importance of the PtdIns(3,4)P2-PLEKHA1/2 
interaction in these contexts is confirmed by the use of PH-domain mutant forms of PLEKHA1/2 in 
these studies, and the mechanism of action of these proteins may be via the ability to restrain AKT 
activity, either via recruitment of proteins like the PTPL1 phosphatase, or via direct competition with 
AKT for available PtdIns(3,4)P2 [1].  While current evidence suggests PLEKHA1/2 expression in 
platelets is likely to be low relative to lymphocytes [47, 50], even at limited global cellular abundance 
these high affinity PtdIns(3,4)P2 effectors may be suitably poised to respond to the localised 
concentrations of PtdIns(3,4)P2 described in cellular processes regulated by this phosphoinositide [3, 
4, 18, 71], and their functional role in platelets warrants further investigation.  It is worth noting that, 
while much published evidence supports the marked preferential affinity of PLEKHA1 and 2 for 
PtdIns(3,4)P2 over other phosphoinositides [1, 2], it is clear that these proteins do demonstrate some 
affinity for PtdIns(3,4,5)P3 [34, 55, 60, 72], but whether this is sufficient for functional responses to 
PtdIns(3,4,5)P3 in vivo remains to be determined.  
Beyond the aforementioned candidates, our interactome contained a broader set of PH domain-
containing proteins, including RASA3, PHLDB1, MTMR5, GAB3, SWAP70, ADAP1 and 
PLEKHO2.  With the exception of RASA3, the functional roles of these proteins in platelets remain 
unknown, yet it is noteworthy that, in other cell types, several have the ability to regulate the 
signalling and trafficking of integrins and other receptors, and to orchestrate dramatic changes in 
cytoskeletal organisation and membrane morphology.  These processes are not only known to be 
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regulated by PtdIns(3,4)P2  [1, 2, 14] and are critical for the function of a wealth of cell types, but are 
also of fundamental importance for platelet function in haemostasis and thrombosis, suggesting an 
important role for PtdIns(3,4)P2 acting through such effectors in this cell type [73, 74].  This would 
correlate with alterations in membrane morphology, platelet contractility and thrombus organization 
observed with platelets lacking the PtdIns(3,4,5)P3-phosphatase SHIP1, which demonstrate a loss of 
agonist-driven PtdIns(3,4)P2 [32, 33, 64, 65].   
PHLDB1 (also known as LL5α) has been shown previously to support AKT phosphorylation and 
GLUT4 translocation in adipocytes, to serve as a microtubule anchoring factor, and to support 
lamellipodial persistence and integrin internalisation in migrating tumour cells [42, 75, 76].  MTMR5 
is an inactive phosphatase that has been proposed to act as a scaffolding protein and a GEF for RAB-
family small GTPases [77-79], while ADAP1 is a GAP with dual PH domains; the first holds affinity 
for PtdIns(3,4,5)P3, and the second for both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 [43]. ADAP1 has been 
shown to possess GAP activity for ARF6, a small GTPase with roles in vesicular trafficking 
(including platelet endocytosis [80]) and cytoskeletal arrangements, and accordingly ADAP1 has been 
implicated in control of the actin cytoskeleton, and the trafficking and sur ace expression of GPCRs 
and integrins [43, 81-84].  While GAB1 and 2 hold various functional roles in different cell types and 
are known to possess affinity for 3-phosphoinositides [85, 86], GAB3 has received more limited 
functional characterisation.  It has been shown to regulate AKT activation and cancer cell 
proliferation in human glioma [87], and to our knowledge we provide the first evidence of the affinity 
of GAB3 for PtdIns(3,4)P2.  Although mice deficient in GAB3 display a normal platelet count [88], 
GAB3 appears to be well expressed in this cell type [47], and its functional role remains unknown. 
SWAP70 can serve as an actin-bundling protein, to regulate the actin cytoskeleton and lamellipodia 
formation in a PtdIns(3,4)P2-dependent manner [44, 89, 90].  In contrast, PLEKHO2 is a poorly-
characterised protein, so far known only to support macrophage survival [91], although it appears to 
be well expressed in platelets [47].   
It is particularly interesting that our data suggest RASA3 to hold affinity for PtdIns(3,4)P2.  This RAS 
and RAP GAP is essential for platelet activation and lifespan, and serves as a key regulator of αIIbβ3 
outside-in signalling downstream of PI3K [41, 48].  While RASA3 has demonstrated affinity for 
PtdIns(4,5)P2 and PtdIns(3,4,5)P3 [34, 41, 92] to our knowledge we provide the first evidence of its 
affinity for PtdIns(3,4)P2, and this interaction may support PtdIns(3,4)P2 in promoting sustained αIIbβ3 
outside-in signalling. Indeed, given the association between integrin activation and PtdIns(3,4)P2 
generation in platelets, it is noteworthy that PtdIns(3,4)P2 effectors such as RASA3, PHLDB1 [75, 76] 
and ADAP1 [84] identified in our screen are linked to integrin signalling and function.   
In addition to PH domain-containing proteins, our dataset contains numerous other potentially novel 
PtdIns(3,4)P2 effectors.  If the majority of the proteins identified interact directly with PtdIns(3,4)P2, 
as our network interaction analysis suggests, it is possible they do so via other protein domains, such 
as the PX domain of SNX2 [93], or via other clusters of basic amino acids within their sequence [51, 
60].  Among these proteins is PNKD, which we previously revealed to possess affinity for 
PtdIns(3,4,5)P3 [34].  PNKD can regulate the proliferation, adhesion and migration of cancer cells via 
a relationship with MLC2 and FAK (a key protein in platelet adhesive signalling), as well as the 
PtdIns(3,4,5)P3/ PtdIns(3,4)P2 effector AKT [94].  PNKD appears to be well expressed in platelets and 
may represent an important new 3-phosphoinositide effector regulating adhesive signalling in this cell 
type.  Conversely, another protein we have shown to hold affinity for both PtdIns(3,4,5)P3 and 
PtdIns(3,4)P2, ARMX3, can suppress non-small cell lung cancer invasion via suppression of AKT 
phosphorylation [95].  The identification of proteins such as SQOR, MICU1 and DECR1 suggests a 
potential role for PtdIns(3,4)P2 in mitochondrial function, while the identification of receptors such as 
P2RX1, GPVI and F2RL3 suggests an importance for intramembrane lipid-protein interactions.  Of 
note, P2RX1 has been shown previously to hold affinity for PtdIns(3,4)P2 (in addition to 
PtdIns(4,5)P2, known to regulate its function) [96], while GPVI and F2RL3 couple robustly to PI3K 
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signalling in platelets [34, 97].  The identification of F2RL3, in addition to GNAS2, is particularly 
interesting given recent work shedding light on the regulation of GPCR-G protein-coupling by 
PtdInsP2 [98, 99].   
 
5. Conclusions   
It is tempting to envisage how many of the proteins identified in our screen can underpin both hitherto 
unknown, and recently-defined, roles for PtdIns(3,4)P2 in a range of cell types, including the 
regulation of events like protein trafficking, membrane remodelling, and cell migration.  Indeed it is 
intended that this study will support significant advancement of the understanding of PtdIns(3,4)P2’s 
cellular roles, by providing a springboard for the functional characterisation of the proteins identified 
and their relationship with this phosphoinositide.   The value of this approach has been demonstrated 
previously for PtdIns(3,4)P2 effectors such as PLEKHA1/2 and Lamellipodin, as well as for effectors 
for other phosphoinositides.  Alongside effector characterisation, continued progress in the ability to 
visualise and quantify PtdIns(3,4)P2 in distinct endogenous contexts, and to understand its synthesis 
and degradation, will be vital for a comprehensive understanding of this phospholipid.  Determining 
the relationship between PtdIns(3,4)P2’s specific functional roles, and its significance as one 
component of a wider phosphoinositide network (e.g. as a breakdown product of PtdIns(3,4,5)P3,  or a 
precursor for PtdIns(3)P), will be interesting.  It is clear these roles are not mutually exclusive, and 
much remains to be understood about PtdIns(3,4)P2’s functional interplay with PtdIns(3,4,5)P3, since 
PtdIns(3,4)P2 can both support and compete with PtdIns(3,4,5)P3 for effectors, while each lipid can 
also act independently [16, 17].  A major experimental challenge is that PtdIns(3,4)P2 function appears 
to be highly context-specific, potentially dependent on the cell type, the nature of the initiating 
stimulus, the presence of other positive or negative coincidence signals, and the available combination 
of effectors.  The spatiotemporal properties of the PtdIns(3,4)P2 signal will be critical in permitting it 
and other phosphoinositides to selectively regulate effectors, including individual AKT isoforms [18, 
71], and it seems evident that PtdIns(3,4)P2 localisation often dictates function [2-4].  A greater 
understanding of these factors, along with the potential functional significance of fatty acyl 
composition [11, 100, 101], will contribute to an improved understanding of phosphoinositide biology 
in health and disease. 
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Figure legends 
Figure 1. Affinity proteomics workflow for the identification of human platelet PtdIns(3,4)P2-
binding proteins. Platelets were isolated from the whole blood of healthy human donors, and lysed 
under mild non-denaturing conditions.  Platelet lysates were incubated with PtdIns(3,4)P2-coupled 
beads for the capture of PtdIns(3,4)P2-binding proteins.  For control samples, platelet lysates were 
either incubated with blank control beads, or preincubated with free PtdIns(3,4)P2 prior to incubation 
with PtdIns(3,4)P2-coupled beads, to assess binding specificity.  For label-free proteomic analysis, 
captured proteins were eluted off the beads, gel-fractionated, and subjected to in-gel reduction, 
alkylation and trypsin-digestion prior to LC-MS/MS.  For TMT analysis, proteins were subjected to 
on-bead reduction, alkylation and trypsin digestion, prior to labelling, pooling, high pH off-line RP-
HPLC, and LC-MS3.  Mass spectrometry data were subjected to quantitative filtering and assessed 
using a range of bioinformatics tools.    
Figure 2. Global analysis of the label-free proteomics data.  For initial visualisation and quality-
control of the label-free proteomics data, T3PQ area values were log2 transformed, pooled, filtered, 
and imputed, as discussed in Supplementary Methods. Volcano plots were generated for 
PtdIns(3,4)P2-coupled bead pull downs versus control blank bead pull downs (A), and for 
PtdIns(3,4)P2-coupled bead pull downs versus PtdIns(3,4)P2-coupled bead pull downs following 
preincubation of the platelet lysate with free PtdIns(3,4)P2 (B), and presented displaying the 
difference in log2 means against negative log p values. A selection of well-characterised, and also 
potentially novel, PtdIns(3,4)P2 effectors identified in this screen are highlighted. (C) Profile plots for 
selected proteins derived from the label-free analysis of a representative blood donor, displaying a 
range of protein behaviours against the background of all proteins for non-imputed data.  PLEKHA1, 
DAPP1 and AKT2 represent well-established PtdIns(3,4)P2 binding proteins. PLEKHA1 was captured 
specifically and abundantly on the PtdIns(3,4)P2-coupled beads and thus passes data filtering 
following imputation of control values. DAPP1 displays some abundance in control samples, due to 
non-specific capture of this highly-abundant platelet protein, but displays significant enrichment on 
the PtdIns(3,4)P2-coupled beads, requires no imputation, and passes data filtering.  The archetypal 
PtdIns(3,4)P2-binding protein AKT2 displays specific capture on the PtdIns(3,4)P2-coupled beads, but 
is lost following imputation of control values due to its low abundance.  UBAP2L is representative of 
many proteins displaying non-specific capture on the PtdIns(3,4)P2-coupled beads versus blank 
beads, which were not susceptible to competition using free PtdIns(3,4)P2.  VDAC is representative of 
proteins captured non-specifically across all bead conditions.  These observations contributed to the 
adoption of our final integrated strategy to define the PtdIns(3,4)P2 interactome using both label-free 
and TMT analysis, as discussed in Supplementary Methods.   
Table 1.  Selected components of the human platelet PtdIns(3,4)P2 interactome.  For label-free 
data, presented are mean values for LC-MS/MS analysis of protein capture on PtdIns(3,4)P2-coupled 
beads across three independent blood donors.  Proteins are ranked based on mean abundance. For 
TMT data, presented are combined ratios from two independent blood donors for comparisons of 
PtdIns(3,4)P2-coupled bead capture versus blank control bead capture (PIP2/Control), and 
PtdIns(3,4)P2-coupled bead capture versus PtdIns(3,4)P2-coupled bead capture following 
preincubation of the platelet lysate with free PtdIns(3,4)P2 (PIP2/PIP2+).  Shown is a spectrum of 
proteins identified in the screen, with the full data set presented in Table S1.  
Area, T3PQ abundance values; score, the total score of the protein, which is the sum of all peptide 
XCorr values for that protein above the specified score threshold; coverage, the percentage of the 
protein sequence covered by the identified peptides; peptides, the number of distinct peptide 
sequences identified for the protein; PSM, the total number of identified peptide sequences for the 
protein, including those redundantly identified. 
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Figure 3. Immunoblotting of selected PtdIns(3,4)P2 effectors captured on PtdIns(3,4)P2-coupled 
beads.  Affinity capture of PtdIns(3,4)P2-binding proteins was carried out as detailed for label-free 
proteomics experiments, and eluted proteins were separated by SDS-PAGE and subjected to LI-COR 
immunoblotting using specific antibodies.  Input represents 3% of affinity capture input.  GAPDH 
represents a negative control.  Results are representative of three independent experiments. 
Figure 4. PH domain analysis of identified PtdIns(3,4)P2-binding proteins.  (A)  Amino acid 
sequence alignment of the PH domains of proteins identified in the PtdIns(3,4)P2 interactome 
confirms the presence of conserved lysine (K) and arginine (R) residues (red boxes), including key 
components of the putative PtdIns(3,4)P2/PtdIns(3,4,5)P3-binding pocket in the β1-β2 strand region.  
Basic residues at other positions are also likely to contribute to PtdIns(3,4)P2/PtdIns(3,4,5)P3 
binding. The key lysine and arginine residues that contribute to SWAP70 and OSBL8’s non-canonical 
mode of binding to PtdIns(3,4)P2/ PtdIns(3,4,5)P3  are indicated in blue boxes. Additional glycine (G), 
phenylalanine (F), tyrosine (Y) and tryptophan (W) residues supporting the alignment are indicated 
(orange boxes), although these are not necessarily relevant for 3-phosphoinositide binding.  For 
PLEKHA1/2 and ADAP1, the C-PH domains are presented, which have been previously 
demonstrated to mediate the PtdIns(3,4)P2-binding of these proteins.  (B) Domain analysis of the 
PtdIns(3,4)P2 interactome reveals the significant enrichment of pleckstrin homology (PH) domain-
containing proteins. The number of PH domain-containing proteins in the interactome, the fold 
enrichment, and a Benjamini p value are shown.  
Figure 5. Characterisation of the MTMR5 PH domain (A) Assessment of the structure of the PH 
domain of mouse MTMR5 (PDB 1V5U) reveals a characteristic seven-stranded β-sandwich with a C-
terminal α-helix.  Mapping of the most highly conserved basic residues (red) from the PH domain 
alignment in Figure 4 onto this structure (these residues are identical between the human and mouse 
MTMR5 PH domain) suggests a phosphoinositide-binding pocket comparable to that previously 
defined for other PtdIns(3,4)P2/PtdIns(3,4,5)P3 effectors.  (B)  Coommassie-stained SDS-PAGE gel of 
the purified human MTMR5 PH domain expressed as a GST-fusion protein.  (C)  The GST-tagged 
MTMR5 PH domain shown in (B) was assessed for its phosphoinositide selectivity using a 
phosphoinositide binding array, confirming affinity for PtdIns(3,4)P2 and PtdIns(3,4,5)P3.  Of note, 
MTMR5 was identified with one blood donor in our previous screen for PtdIns(3,4,5)P3 effectors 
[34], but was not identified with the other donors, potentially due to low affinity for this 
phosphoinositide.  Results are representative of three independent experiments.    
Figure 6. Interaction network analysis of the PtdIns(3,4)P2 interactome.  To identify interactions 
within the experimentally-derived PtdIns(3,4)P2 interactome and hence to determine whether some 
proteins identified may not interact directly with PtdIns(3,4)P2 , the complete protein set was 
subjected to analysis using STRING version 11, screening for experimentally-determined (pink 
connections) and database-curated (blue connections) interactions, with a confidence score of 0.9.   
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Table 1.  Selected components of the human platelet PtdIns(3,4)P2 interactome.  For label-free data, presented are mean values for LC-MS/MS analysis of 
protein capture on PtdIns(3,4)P2-coupled beads across three independent blood donors.  Proteins are ranked based on mean abundance. For TMT data, 
presented are combined ratios from two independent blood donors for comparisons of PtdIns(3,4)P2-coupled bead capture versus blank control bead capture 
(PIP2/Control), and PtdIns(3,4)P2-coupled bead capture versus PtdIns(3,4)P2-coupled bead capture following preincubation of the platelet lysate with free 
PtdIns(3,4)P2 (PIP2/PIP2+).  Shown is a spectrum of proteins identified in the screen, with the full data set presented in Table S1.  
Area, T3PQ abundance values; score, the total score of the protein, which is the sum of all peptide XCorr values for that protein above the specified score 
threshold; coverage, the percentage of the protein sequence covered by the identified peptides; peptides, the number of distinct peptide sequences identified 
for the protein; PSM, the total number of identified peptide sequences for the protein, including those redundantly identified. 
   
Label-free         TMT   
Accession Gene Description Mean area 
Mean 
score 
Mean 
coverage (%) 
Mean 
peptides 
Mean 
PSM PIP2/Control PIP2/PIP2+ 
Q9UN19 DAPP1 
Dual adapter for phosphotyrosine and 3-phosphoinositide / 
BAM32 6.17E+09 557.1 77.0 22.3 188.3 52.8 18.7 
Q8N490 PNKD Probable hydrolase PNKD 1.49E+08 53.6 32.8 10.0 18.3 7.3 4.5 
Q14644 RASA3 Ras GTPase-activating protein 3 1.34E+08 129.3 46.6 31.7 45.7 35.9 5.6 
Q9HB19 PLEKHA2 
Pleckstrin homology domain-containing family A member 2 
/ TAPP2 1.07E+08 67.8 47.0 14.7 25.0 82.4 11.2 
Q9HB21 PLEKHA1 
Pleckstrin homology domain-containing family A member 1 
/ TAPP1 5.85E+07 69.4 48.0 15.3 28.0 99.6 16.3 
Q86UU1 PHLDB1 Pleckstrin homology-like domain family B member 1 / LL5α 3.91E+07 38.1 11.2 11.7 12.3 9.7 4.0 
Q9UH62 ARMCX3 Armadillo repeat-containing X-linked protein 3  2.69E+07 34.8 34.4 10.3 12.3 5.8 3.2 
O95248 SBF1 Myotubularin-related protein 5 / MTMR5 2.32E+07 72.6 17.5 21.7 24.7 10.6 2.1 
Q53H12 AGK Acylglycerol kinase 2.10E+07 27.4 33.3 9.7 10.3 6.3 8.3 
Q13613 MTMR1 Myotubularin-related protein 1 2.02E+07 31.0 22.4 11.0 13.0 10.6 2.3 
Q9Y6N5 SQOR Sulfide:quinone oxidoreductase 1.76E+07 21.3 19.7 7.3 8.0 4.9 5.2 
P53007 SLC25A1 Tricarboxylate transport protein / TXTP 1.52E+07 7.9 13.8 4.0 4.3 7.2 3.9 
Q16698 DECR1 2,4-dienoyl-CoA reductase 1.18E+07 13.3 18.2 4.7 4.7 5.3 4.4 
Q8WWW8 GAB3 GRB2-associated-binding protein 3 8.53E+06 12.6 8.2 4.7 5.3 7.9 4.0 
Q9UH65 SWAP70 Switch-associated protein 70 3.92E+06 5.3 3.8 2.3 2.3 5.0 1.5 
O75689 ADAP1 Arf-GAP with dual PH domain-containing protein 1 3.43E+06 6.0 8.9 3.3 3.3 34.5 11.5 
Q8TD55 PLEKHO2 Pleckstrin homology domain-containing family O member 2 2.32E+06 9.5 9.0 2.3 3.0 4.0 1.7 
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/ PKHO2 
Q9BZ67 FRMD8 FERM domain-containing protein 8  1.81E+06 2.4 3.8 1.7 1.7 4.9 2.8 
Q9BZF1 OSBPL8 Oxysterol-binding protein-related protein 8 / OSBL8 9.81E+05 2.4 1.2 1.0 1.0 6.2 1.6 
P31751 AKT2 RAC-beta serine/threonine-protein kinase / PKBβ 6.23E+05 4.5 4.6 2.3 2.3 9.6 8.9 
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Highlights 
 A global screen for PtdIns(3,4)P2-interacting proteins in human platelets. 
 PtdIns(3,4)P2 interactors span a range of functional classes, including regulators of protein 
trafficking and cytoskeletal organisation. 
 The PH domain of MTMR5 shows affinity for PtdIns(3,4)P2 and PtdIns(3,4,5)P3.   
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